Objective: To examine the available scientific evidence for answers to clinically relevant questions on the effectiveness and tolerability of antidepressant drugs (ADs) for the long-term treatment of depression.
I n the preceding metareview, 1 we focused on some salient problems in acute-phase clinical management of depression. In this overview, we define long-term treatment with an AD as the prescription of the medication for more than 2 to 3 months following the acute-phase treatment. 2 Essentially, there are 2 situations in which long-term treatment is advised in clinical practice. The first occurs when patients do not respond or respond only partially to acute-phase treatment. The second occurs when patients receive long-term treatment after acute-phase treatment response to prevent return of symptoms. We will consider separately the currently available best evidence on the effectiveness and safety of ADs for these 2 indications.
Methods
We identified relevant systematic reviews from the Cochrane Database of Systematic Reviews. When no complete Cochrane review was available, we looked in PubMed (1966 to July 2006) for relevant systematic reviews or individual RCTs.
Long-Term Treatment With Antidepressants for Patients With No, or Partial, Response to Acute-Phase Treatment

Background
The remission rates after acute-phase treatment with ADs are known to be in the range of 30% to 40% 3,4 -often, only moderately higher than those observed for placebo treatment in RCTs. 5 The first phase of the STAR*D, the recent large-scale, collaborative US study in which 2876 patients with major depression received flexible dosages of citalopram in 23 psychiatric and 18 primary care settings for up to 14 weeks, reported a remission rate of 28%, just below this range. 6 Clearly, up to three-quarters of patients who receive a course of acute-phase treatment with ADs will need further active treatment. Is there a place for further treatments with ADs, when initial AD therapy has essentially failed? Further, if AD therapy has been unsuccessful, which of the possible pharmacotherapeutic strategies-continuation of the current treatment, dosage increase, switch to another AD, or augmentation with another drug 7 -should the clinician choose? Because this is a review of ADs, we focus on them and only briefly mention agents other than ADs or psychotherapies.
Continuing on Same Medication at Same Dosage. Concerning increasing, switching, or augmenting strategies, several trials mentioned below employed continuing on the same medication at the same dosage as a comparison arm. It should be noted that continuing on the same medication at the same dosage will induce remission in a substantial minority of patients even if they do not show remission at the end of the acute-phase treatment.
In patients who were still fully symptomatic after at least 6 weeks of treatment with 20 mg daily of fluoxetine, continuing at the same dosage of the same drug for a further 6 weeks resulted in a remission rate of 18%. 8 Similarly, among patients who did not respond to 3 weeks of fluoxetine 20 mg, continuing the same dosage for an additional 5 weeks produced a remission rate of 33%. 9 When patients with major depression in partial remission (indicated by an average HDRS score of 12.2) were continued on the same medication (mean daily dosage of fluoxetine 33 mg or equivalent) for 20 weeks, 13% remitted. 10 Dosage Increase. Increasing the dosage of the initial AD is the most frequently recommended approach. 7, [11] [12] [13] However, a systematic review failed to identify a strong evidence base for this strategy. 14 A more recent review also found direct evidence that there was no benefit from increasing the SSRI or TCA dosage. 15 We repeated the search in July 2006, identifying 5 RCTs that examined dosage-increase strategies for SSRIs and maprotiline. 9, [16] [17] [18] [19] · Dornself et al (1989) 9 : Patients who did not respond to 3 weeks of treatment with fluoxetine 20 mg (n = 371) were randomly assigned to fluoxetine 20 mg or 60 mg for an additional 5 weeks. At the study's end point, the response rates were 41% and 45%, respectively, and the remission rates were 33% and 36%, respectively. · Schweizer et al (1990) 16 : Patients who had not responded to 3 weeks of treatment with fluoxetine 20 mg (n = 78) were randomized to a further 5 weeks of fluoxetine 20 mg or an increased dosage of 60 mg. The end point response rates were 49% and 50%, respectively. effects (n = 173) were randomly assigned either to continue on the same dosage or to increase the dosage to 40 mg of paroxetine or 150 mg of maprotiline for an additional 3 weeks. The response rates at end point were 64% for those who stayed on the same dosage and 70% for those who increased the dosage. · Schweizer et al (2001) 18 : Patients who had not achieved remission on 3- week, open-label treatment with sertraline 50 mg (n = 75) were randomized to 5 more weeks of double-blind treatment with either 50 mg or 150 mg of the same drug. The remission rates at 8 weeks were 32% and 47%, respectively. Growth curve analyses revealed no significant difference between the 2 groups on any of the outcome measures. · Licht and Qvitzau (2002) 19 : Patients who had not responded to 6 weeks of treatment with sertraline up to 100 mg (n = 295) were randomized to an additional 5 weeks of sertraline 100 mg, sertraline 200 mg, or sertraline 100 mg plus mianserin 60 mg. The remission rates were 38%, 29%, and 44%, respectively.
In none of these trials was the dose increase strategy statistically significantly different from the strategy to remain on the initial dosage. A recently published Cochrane systematic review dealt with the same clinical question. Incorporating wider inclusion criteria, the authors reached the same conclusion. 20 It is remarkable that, contrary to the accepted wisdom, no randomized trial has ever demonstrated the superiority of increasing the dosage of fluoxetine, sertraline, paroxetine, or maprotiline over maintaining the initial dosages.
Switching to Another Antidepressant. Switching to another AD, possibly from a different chemical class, represents a second favoured choice among clinicians. 11, 12 We were able to locate no systematic review on this topic and only a handful of relevant RCTs. Three trials aimed to address differential responses among different classes of ADs:
· The STAR*D study directly informs this question because nonresponders to the open trial with citalopram (n = 727) were randomly allocated to sustained-release bupropion, sertraline, or extended-release venlafaxine. 21 The trial therefore compared a switch to an AD of the same class and a switch to a different class. The remission rate was not statistically different between the 3 arms (21%, 18%, and 25%, respectively), nor were there differences in terms of tolerability or side effects.
· Step 3 of the STAR*D study compared treatment with mirtazapine and nortriptyline for those who failed to respond to 2 consecutive medication treatments (first citalopram and then bupropion, sertraline, venlafaxine, citalopram plus bupropion, or citalopram plus buspirone) (n = 235). Again, the remission rates did not differ significantly between the 2 alternatives (16% and 20%, respectively). 22 · One old cross-over study compared fluvoxamine and oxaprotiline (a selective noradrenergic reuptake inhibitor) in patients with DSM-III major depression resistant to adequate pharmacotherapy with TCAs (n = 71). In the first treatment period, 27% responded to oxaprotiline but 0% responded to fluvoxamine (P < 0.001). When nonresponders to each drug was switched over to the other drug, 38% responded to oxaprotiline and 10% responded to fluvoxamine (P = 0.03). 23 Only one trial directly examined the effectiveness of the switching strategy vis-à-vis the strategy to continue the same medication: · Ferreri et al 8 randomly assigned patients who were still fully symptomatic after at least 6 weeks of treatment with fluoxetine 20 mg to continue the same dosage, to switch to mianserin, or to augment fluoxetine with mianserin for 6 more weeks. The remission rates were 18%, 36%, and 44% respectively (P = 0.06). In this instance the strategy of switching does appear superior to continuing the same medication. Overall, however, the paucity of evidence prohibits us from generalizing beyond switching fluvoxamine with oxaprotiline or fluoxetine with mianserin. Although very large, the STAR*D study was still underpowered to statistically detect the difference of 18% for sertraline, compared with 25% for venlafaxine (for a type I error of 0.05, the type II error = 0.53), let alone the difference of 16% for mirtazapine, compared with 20% for nortriptyline (for a type I error of 0.05, the type II error = 0.88). These studies therefore provide no overwhelming evidence in favour of switching to a compound of the same class or of a different class or to a particular compound in the switching strategy.
Augmentation With a Second Antidepressant. Adding a second AD is another frequently recommended strategy. Because this is a review of the long-term efficacy of ADs, we will not deal with augmentation by lithium, thyroid hormones, or any other non-AD.
Augmentation of an SSRI by a noradrenergic antidepressant, mianserin, has been studied in 2 RCTs. 8, 19 In a trial by Ferreri et al, 8 fluoxetine plus mianserin produced a higher remission rate than mianserin alone or fluoxetine alone among patients nonresponsive to fluoxetine (P = 0.06). In a trial by Licht and Qvitzau, 19 the combination of sertraline plus mianserin again had the highest remission rate among patients nonresponsive to initial sertraline, although the difference was not statistically significant.
Another small trial compared augmentation by mirtazapine (which is chemically related to mianserin) with placebo addition among patients nonresponsive to adequate SSRI, bupropion, or venlafaxine treatment. The remission rate was 46% with mirtazapine augmentation and 13% with placebo augmentation (P = 0.068). 24 The STAR*D study made another randomized comparison among nonremitters to the initial open trial of citalopram by adding either sustained-release bupropion or buspirone to the existing citalopram. 6 The remission rates did not differ between the 2 arms (30% for both). Augmentation with bupropion resulted in a lower dropout rate due to intolerability, but it did not differ in any other index of side effects, such as the absolute burden of side effects.
Clinical Application of the Evidence
The somewhat limited evidence allows several cautious conclusions: · There is no good evidence that increasing the dosage of the initial AD is an effective strategy. This conclusion is in full accordance with 2 systematic reviews that found no, or marginal, increase in effectiveness, at the expense of a substantial increase in side effects, between initial low-dose, compared with high-dose, SSRI 25 or TCA 26 prescription strategies. It also accords with a recent trial of a serotonin-norepinephrin reuptake inhibitor that compared the standard as opposed to a higher dosing strategy of venlafaxine with SSRI nonresponders and found no significant efficacy difference on the intention-to-treat basis. 27 These findings are in stark contrast to the actual preferences of practising psychiatrists, whose first choice was to increase the dosage, both in North American surveys 12, 13 and in a UK survey. 11 · The common wisdom that switching should be to a chemically different class of AD seems to be more opinion-based than evidence-based. Just as with the initial choice of AD, there seems to be freedom of choice in regard to the second-line AD, as far as monotherapies are concerned.
· The augmentation strategy does appear to have some limited support from randomized evidence. Mianserin and its chemically related drug, mirtazapine, appear to augment SSRIs when SSRIs initially fail to bring about response. Although beyond the scope of this review, it is noteworthy that there is also increasing support for augmentation with several non-AD agents, including lithium 28 and thyroid hormone, [29] [30] [31] [32] as well as for augmentation with cognitive-behavioural therapy 10 and, possibly, electroconvulsive therapy. 33 It is very difficult to summarize and interpret the findings of the STAR*D, the biggest pragmatic study to date on managing major depression, because no substantial differences were found among the randomized comparisons and because any apparent differences between the separate randomized phases of the study are hard to interpret, since they are not direct comparisons. The absence of a common comparator means that even formal indirect comparisons are not possible. One must be very cautious, therefore, in concluding that the STAR*D results suggest that the augmentation strategy may be superior to switching among monotherapies. 34 It is important to remember that almost all the studies reviewed here focus on depression severity, response, and (at best) remission at the end of an additional 4 to 8 weeks of treatment after failure of initial acute-phase treatment. We lack any information about broader quality of life or social functioning, nor do we have information about rare side effects such as suicidality, discontinuation symptoms, and teratogenecity with these increasing, switching, or augmenting strategies.
Clinically, the lack of strong evidence in favour of one treatment strategy over another makes it difficult and unwise to make clear-cut treatment recommendations. Rather, the appropriate strategy for any individual patient will need to take into account the available evidence, patient preference, and clinical expertise.
Long-Term Treatment With ADs for Patients Remitted on Acute-Phase Treatment
Evidence One systematic review (search date 2000 and publication date 2003) 35 found that continuing AD drug treatment after recovery dramatically reduced the proportion of patients who relapsed over 1 to 3 years, compared with placebo. The average rate of relapse on placebo was 41%, compared with 18% on active treatment. The RR remained constant regardless of the duration of treatment before randomization or the duration of treatment after randomization, up to 36 months (Figure 1 ). Since this systematic review was published, several further trials of relapse prevention with continuing ADs have been published. [36] [37] [38] [39] [40] [41] The results of these trials are consistent with the systematic review, and the results of the metaanalysis could only be reversed by a powerfully negative megatrial with several thousand patients, which is perhaps unlikely ever to be conducted.
Clinical Application of Evidence
The evidence base for this second indication is very different for the first indication: here, there is overwhelming evidence of benefit for the average patient in the trials. Figure 1 shows that the RR of relapse was virtually constant at 0.46, with little heterogeneity among trials, as suggested by I-squared statistics of 0.6%. I-squared statistics quantify the absolute degree of heterogeneity among combined trials; 30% or 50% have been suggested as indicating the existence of heterogeneity, 42 and 0.6% represents by any measure a very low degree of heterogeneity.
A precise and consistent average beneficial effect is very useful but still needs to be applied thoughtfully to individual patients. How can we apply this constant RR to the individual patients we see from day to day-in other words, how can we individualize the results from a metaanalysis? 43 We will take 3 clinical examples.
Clinical Vignette 1: A Woman, Aged 55 Years. This patient was married, but she and her husband separated 10 years ago, and she has lived ever since with her only son, who is about to leave for his new job in a foreign country. Her mother also suffered from chronic, recurrent depression and eventually killed herself in her 50s. This patient has a history of 6 lifetime major depressive episodes, with 3 in the past 2 years. She has no history of manic or hypomanic symptoms. During depressive episodes, she becomes suicidal, and made a serious suicide attempt during her last episode. After some vigorous treatment with a high dosage of a TCA for the most recent episode, she is now in partial remission but suffers from some residual symptoms.
Let's consider Vignette 1. What might be your predicted possibility of relapse within 12 months for this patient? Some psychiatrists might say close to 100%, others might say 80%, and still others might say 50%. From among the 35 studies pooled in Figure 1 , patients recruited in the trial by Kishimoto et al 44 might very well resemble her: they were mostly female patients, their average age was in the mid-50s, and they had, on average, 2.6 depressive episodes in the last 2 years and, on average, 5.1 lifetime depressive episodes. In this trial, the relapse rate within 18 months was 13/14 on placebo, or 93%. 44 We therefore predict that, for this patient, the PEER of relapse within a year is 80% to 90%.
Based on this PEER and on the constant RR obtained from the most comprehensive homogeneous metaanalysis, we would then predict that keeping this patient on an AD for 1 year would halve the relapse rate from 80% to 90% to 40% to 45%. Would she be better off on an AD for 12 more months? That would depend on the patient's own personal preferences, but most patients and clinicians would probably agree to continuation treatment.
Clinical Vignette 2: A Man, Aged 55 Years. This patient has recently recovered from a second major depressive episode, the first one having occurred in his 30s. He quit his job when he first suffered from depression but started working at another company when his depression lifted completely within 6 months of treatment. He has worked with the same company for over 20 years now, but his wife reported that, with increasing age and increasing responsibility in his job, he had been somewhat dysthymic for the past several years. He gradually became more depressed, until he sought psychiatric help about 3 months ago. He has responded well to fluoxetine 30 mg daily but is not yet fully asymptomatic.
In this vignette, what is your predicted possibility of relapse within 1 year for this male patient? Well, it is of course hard to predict for certain, but he might be a typical patient represented in the systematic review by Geddes et al. 35 For example, in the Versiani et al 45 trial of reboxetine, the median number of previous episodes was 3; the average HDRS score was around 30 at the beginning of the acute phase treatment and around 15 at its end. For subjects randomly assigned to placebo after acute-phase treatment, the relapse rate was 56% within 12 months.
Let us assume that the PEER for our hypothetical patient is 50%. Placing him on a continued AD will most likely reduce the possibility of relapse to 25%. Would he accept continuation treatment? Probably yes.
Clinical Vignette 3: A Man, Aged 45
Years. This patient is a company executive who had been functioning well until several months ago but has had his first major depressive episode after failure of a filial company for which he was responsible. This fiasco was due to an unpredictable change in the market and was not his fault at all. He was started on fluoxetine 20 mg and recovered within 2 months without any residual symptoms. Moreover, the company has also recovered quickly from the loss. Further, this patient has a very supportive family.
In this vignette, most clinicians would agree that the PEER for relapse for patient 3 is much lower than for patients 1 and 2-perhaps 20% to 30% per year. This would lead me to speculate that keeping him on 12 more months of antidepressant would reduce the relapse rate to 10% to 15%, and I wonder whether the cost in terms of time and money, and also in terms of the possible side effects, may be worth the treatment effect. I would reveal all the information to the patient and his family, and should they choose to discontinue, I would fully support their choice.
Side Effects
Again, information on side effects is wanting. The above-mentioned systematic review 35 noted that reported adverse effects were similar to those reported in trials of acute treatment. In one of the pooled trials, 6 people continuing ADs committed suicide, compared with one taking placebo. 35 Whether longer AD treatment increased the rate or degree of discontinuation syndrome is unknown.
Concluding Comments
Our review of the available evidence on long-term treatment with antidepressant medication revealed the precariousness of accepted clinical wisdoms. We found little support for increasing the dosage or for switching after failure of a first AD. The evidence for long-term therapy to prevent relapse suggests that blanket statements of the need for 6 to 12 months of continued AD administration after acute-phase treatment 46, 47 may hinder thoughtful, individualized application of groupwise evidence. Above all, the lack of information regarding such possible, but rare, adverse events as suicidality and discontinuation syndrome is lamentable, especially when we consider long-term treatment with ADs.
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Résumé : Le traitement à long terme de la dépression aux antidépresseurs : un examen narratif
Objectif : Examiner les données probantes scientifiques disponibles pour obtenir des réponses à des questions cliniquement pertinentes sur l'efficacité et la tolérabilité des médicaments antidépresseurs (AD) pour le traitement à long terme de la dépression.
Méthode : Une recherche a été effectuée dans Cochrane Library jusqu'à juillet 2006. Lorsqu'aucune étude complète n'était disponible dans Cochrane, nous avons cherché dans PubMed des études systématiques pertinentes ou des essais contrôlés randomisés individuels.
Résultats : Aucunes données probantes solides ne confirmaient que l'augmentation de la dose de l'AD initial est une stratégie efficace pour les patients qui ont une réponse nulle ou partielle au traitement d'une phase aiguë. Il n'y avait pas de données probantes solides appuyant le fait que changer de classe chimique d'antidépresseur était plus efficace que de changer au sein de la même classe. Les essais randomisés ne comportaient qu'un appui limité à plusieurs stratégies d'augmentation. Il y avait des données probantes solides de l'efficacité d'une thérapie à long terme pour prévenir la rechute chez les patients qui se rétablissaient après un traitement de phase aiguë. L'observation des principes de la médecine fondée sur des données probantes suggérait qu'une application attentive, individualisée des données probantes est plus appropriée que des énoncés généraux.
Conclusions : Les données probantes disponibles appuient en partie l'efficacité de plusieurs stratégies d'augmentation dans la prise en charge de patients qui ont une réponse nulle ou partielle au traitement d'une phase aiguë, et l'application individualisée de données probantes solides en groupe pour le traitement d'entretien aux AD afin de prévenir les rechutes. Cependant, les effets secondaires de ces traitements à long terme aux AD sont mal étudiés et rapportés.
